Insider Purchases: Inside the Buy
Tag: StockMarket
Can Freshpet Make for a Fresh Buy: Insiders & Directors Think So
Freshpet’s stock has tumbled more than 70% from its highs, but insiders keep buying and Wall Street funds are all-in (119% ownership!). With revenue growing, profitability improving, and valuation looking much more reasonable, is this the turnaround treat investors have been waiting for? 🐾🍖
Salesforce (CRM): Insider Buys, AI Clouds, and Customer Armies — Should You Join the Ride?
Salesforce insiders are buying, AI is booming, and institutions are all-in. But is CRM stock really ready to rebound — or just blowing more cloud smoke? ☁️💸
Insiders Are Buying Shares of Applied Optoelectronics. Should You?
Applied Optoelectronics (AAOI) insiders—including the CEO—are buying big while revenue growth accelerates and losses shrink. Institutions already own two-thirds of the stock. But with dilution risk, short sellers circling, and heavy competition, is AAOI a comeback kid—or just another speculative fiber bet?
Financials Paint a Dire Story… But Tronox’s CEO and Insiders See Light in the TiO₂ Pigment
Tronox isn’t just about titanium dioxide anymore—it’s about insider confidence, global reach, and whether this chemical giant’s bright white future is worth your green 💵. From insider purchases to institutional moves, here’s why investors might want to watch TROX closely.
International Flavors & Fragrances Inc. (IFF): Insiders Buy Big, CEO Doubles Down, and the Scent of Value Is in the Air
Insiders at International Flavors & Fragrances (IFF) are loading up on shares—CEO included. With a $500M buyback, big-name institutional holders, and portfolio reshaping, the stock could be brewing a comeback. But is it perfume… or still a whiff of trouble?
How Many Insider Buys Will It Take for The Bull in Enphase Energy to Re-energize?
After a brutal drop, Enphase Energy’s CEO is buying big. Institutions are all in. Margins hold strong. Could this be the spark the solar bull needs?
COO Goes Shopping: Is Molina Healthcare (MOH) a Healthy Buy or Just a Check-Up?
When the COO of Molina Healthcare spends $1.56M on stock, investors notice. With Wall Street titans on board and shares at major support, is this a healthy buy — or a risky patient?
MSCI Keeps Winning — and the CEO Keeps Buying In
MSCI delivers world-class data tools for investors—and its CEO just bought in big. With soaring revenue, recurring subscriptions, and loyal institutions, is this still a buy? Or has the stock outpaced its fundamentals?
Insiders Bought "MicroStrategy" Shares at $90. You’re Paying $394.66. Should You?
MSTR insiders are buying, but not the stock you think. They bought STRC at $90 — while MSTR trades near $400. What gives? We break down the numbers, the Bitcoin twist, and what might be worth nibbling on.
New CEO Buys In at Dave & Buster’s ($PLAY). Who Doesn’t Like a Little PLAY in Their Portfolio — or Life?
New CEO Tarun Lal takes the reins—and a big slice of $PLAY stock. With insiders buying, institutions overloaded, and sales trends improving, could this be the next comeback classic of the “entertainment” era?